Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera  by Draper, Eve et al.
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The  majority  of  cervical  cancers  are  associated  with  infection  by  one  or more Human  Papillomavirus
(HPV)  types  from  just  two  distinct  Alpha-Papillomavirus  species  groups,  A7  and  A9. The  extent  to which
the  current  HPV16/18  vaccines  will  protect  against  other  genetically  related  HPV  types  is of  interest  to
inform  vaccine  implementation,  cervical  disease  surveillance  and  the  development  of second  generation
HPV  vaccines.  The  aim  of  this  study  was  to  determine  the  frequency  and  titer of neutralizing  antibod-
ies  against  a  range  of  A7  (18,  39,  45, 59, 68) and  A9 (16, 31,  33,  35, 52, 58) HPV  types  using  sera  from
individuals  immunized  with  the  bivalent  HPV  vaccine  within  the  school-based,  UK  national  HPV  immu-
nization  programme.  Serum  samples  were  collected  from  69  girls  aged  13–14  years,  a median  5.9 months
(inter-quartile  range,  IQR,  5.7–6.0)  after  their  third  vaccine  dose.  Cross-neutralizing  antibodies  against
HPV31,  HPV33,  HPV35  and  HPV45  were  common  and strongly  associated  with  the  titer  for  the  related
vaccine-type,  but were  considerably  lower  (<1%)  than  their  related  vaccine  type-speciﬁc  response.  The
low  prevalence  of  these  HPV  types  in the  population  and  the ages  within  the study  cohort  suggest  these
responses  are  due  to vaccination.  It  is  unclear  whether  such  low  levels  of  neutralizing  antibodies  would
be  sufﬁcient  to protect  at the  site  of infection  in  the  absence  of  other  immune  effectors  but  the  coinci-
dence  with  HPV  types  reported  from  efﬁcacy  studies  is intriguing.  The  utility  of  neutralizing  antibodies
as  surrogate  markers  of  protection  remains  to be  determined.. Introduction
Virus-like particles (VLP) comprising the major capsid protein
L1) of the Human Papillomavirus (HPV) form the basis of the cur-
ent HPV vaccines, Cervarix® and Gardasil® [1]. Both vaccines target
high-risk’ HPV types 16 and 18, which together are associated with
a. 70% of cervical cancers [2,3], and demonstrate almost complete
rotection against HPV16/18-associated high-grade lesions (cervi-
al intraepithelial neoplasia grade 2+; CIN2+) [4,5].
Peripheral immunization with L1 VLP elicits a systemic, type-
peciﬁc antibody response that coincides with protective immunity
t both cutaneous (Cottontail Rabbit Papillomavirus; CRPV) and
ucosal (Canine Oral Papillomavirus; COPV) sites in pre-clinical
isease models [6,7]. Moreover, naïve animals can be protected
rom subsequent challenge by passive transfer of serum or puriﬁed
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immunoglobulin G (IgG) from L1 VLP immunized animals. Although
the correlates of protection have not yet been deﬁned [8,9], anti-
bodies are the assumed type-speciﬁc immune effectors in humans,
wherein protection against HPV infection is thought to be imparted
by serum antibodies that transudate to the genital mucosa [10–12].
In addition to HPV types 16 and 18, there are another dozen
or so HPV types also associated with cervical disease [2,3,13]
and the majority of these belong to the same distinct Alpha-
Papillomavirus species groups, A7 (HPV18-related: 39, 45, 59, 68)
and A9 (HPV16-related: 31, 33, 35, 52, 58) as the vaccine types
[14,15]. Emerging clinical trial data suggest that the current HPV
vaccines provide a degree of cross-protection against persistent
infection and/or high grade lesions (CIN2+) attributed to some of
these non-vaccine HPV types, particularly HPV31, 33 and 45, but
probably not 52 and 58 [4,16,17]. These ﬁndings appear to coin-
cide with limited pre-clinical data showing that HPV16 and 18 VLP
can induce low level neutralizing antibodies against genetically
Open access under CC BY license.related HPV types in small animals [18,19]. Few published data are
available on the frequency or titer of neutralizing antibodies raised
in vaccinated humans against closely related, non-vaccine types,
HPV31, HPV45, HPV52 and HPV58 [20,21]. A recent study exploring
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lternative dosing schedules suggested that there was little differ-
nce in vaccine-type antibody titers induced by two  or three doses
f Gardasil® [22]. The potential impact of a reduced dosing sched-
le on the induction of vaccine-speciﬁc, cross-reactive antibodies
s unknown.
In this study we have evaluated the propensity for serum from
3 to 14 year old girls immunized with the bivalent vaccine,
ervarix®, within the school-based, UK national immunization pro-
ramme, to cross-neutralize pseudoviruses representing a range of
7 and A9 ‘high risk’ HPV types.
. Materials and methods
.1.  Study samples
Anonymized serum samples were collected, following informed
onsent, from 13 to 14 years old girls approximately six months
fter completion of a three-dose vaccination schedule with the
ivalent HPV vaccine, Cervarix®. The vaccines were delivered
hrough the UK’s school-based national HPV Immunization Pro-
ramme  within the recommended dosing intervals [23].
Anonymized serum samples from infants (6 months to 4 years
ld, males and females) participating in a clinical trial where
onsent had been given for anonymous testing for other vaccine-
elated antibodies were used to gauge the potential for non-speciﬁc
ssay interference. Environmentally acquired HPV infection was
xpected to be rare in this group and, for the present purposes,
e considered these individuals to represent a true HPV negative
opulation; herein referred to as HPV-naïve.
.2. Pseudovirus neutralization assay
Bicistronic vectors (pXsheLL, where X is the Papillomavirus type
rom which the codon optimized L1 and L2 genes were derived)
epresenting the HPV types 16, 18, 31, 45, 52, 58 and Bovine Papil-
omavirus (BPV) were obtained from J.T. Schiller, National Cancer
nstitute, Bethesda, MD,  USA, while p33sheLL and p68sheLL were
btained from H. Faust and J. Dillner, Malmö  University Hospi-
al, Malmö, Sweden. Constructs representing HPV35 (p35sheLL),
PV39 (p39sheLL) and HPV59 (p59sheLL) were generated by the
nsertion of codon optimized genes (Blue Heron, Inc., Bothell,
A, USA) based upon consensus L1 and L2 amino acid sequences
nto p5shell (http://home.ccr.cancer.gov/lco/default.asp). The con-
ensus sequences were derived from NCBI database sequences
HPV35: M74117, X74477; HPV39: M62849; HPV59: X77858,
U918767) and contemporary sequences from anonymous, HPV-
nfected cytology samples (HPV35 L1: JN104062–64; HPV35 L2:
N104065–67; HPV39 L1: JN104068–70; HPV39 L2: JN104071–72;
PV59 L1: JN104073–74; HPV59 L2: JN104075–77).
The production of L1L2 pseudovirus stocks was performed
s described elsewhere [24] using the alternative protocol
http://home.ccr.cancer.gov/lco/ripcord.htm), developed to reduce
he inclusion of excess non-reporter-containing ‘cold capsids’, and
y using luciferase (pGL4.51 [luc2/CMV/Neo]; Promega, Madison,
I) as the encapsidated reporter. Brieﬂy, 293TT cells were trans-
ected with equal amounts of pXsheLL and pGL4.51 [luc2/CMV/Neo]
lasmids (Lipofectamine 2000; Invitrogen, Carlsbad, CA) and the
ncoded proteins expressed for 48 h before the cells were lysed,
he capsids matured overnight in the presence of ribonucleases
RNase Cocktail; Applied Biosystems/Ambion, Austin, TX) and
he double-clariﬁed supernatant subjected to iodixanol gradient
ractionation.
Puriﬁed pseudovirus stocks were titrated on 293TT cells in
uadruplicate, ﬁve-fold serial dilutions and the equivalent of
 Tissue Culture Infectious Dose 50% (TCID50) was  estimated (2011) 8585– 8590
using the Spearman–Karber equation. The average of three such
estimations was made for each pseudovirus stock used in this
study. Pseudovirus-mediated reporter gene transduction of target
cells in both the infectivity and neutralization assays was mea-
sured using the Steady-Glo Luciferase Assay Reagent (Promega)
and the Glomax Multi Detection System (Promega) according to
manufacturer’s instructions.
The  HPV pseudovirus neutralization assay was  performed as
originally described [25] with some modiﬁcation. For the present
study, heat-inactivated (56 ◦C, 30 min) serum samples were ini-
tially screened against all pseudoviruses (at a ﬁnal serum dilution
of 1/20 with pseudovirus) and any serum that demonstrated ≥80%
reduction in the luciferase signal (RLU) relative to the pseudovirus
and cell only controls was  subsequently titrated and an 80% recip-
rocal neutralization titer estimated by interpolation.
It was important to ascertain the appropriate input level of pseu-
dovirus for the neutralization assays. A plot of input TCID50 against
output luciferase signal (RLU) demonstrated that 300 TCID50 was
within the linear range of the assay for all A7, A9 and BPV pseu-
doviruses and a median 3.35 (inter-quartile range, IQR, 3.14–3.56;
n = 4–9 tests per HPV type) Log10 fold over the background level of
the assay; linear regression, r2 = 0.908 (IQR, 0.862–0.933) [26]. The
median level of L1 protein at this level of input, determined for the
A9 pseuodviruses, was 0.04 (IQR, 0.02–0.1) ng/mL. This level is at
least an order of magnitude lower than that reported by Pastrana
et al. [25], as expected, due to the removal of ‘cold capsids’ using the
alternative protocol. However, a comparison of HPV16 and HPV31
neutralization titers derived using 30, 300 and 3000 input TCID50,
spanning ca. 4 Log10 range of L1 protein and ca. 2 Log10 difference
in particle to infectivity ratios between the standard and alter-
native protocol-produced stocks were not signiﬁcantly different
(Wilcoxon paired signed rank test and analysis of trend; p > 0.05).
Thus, 300 TCID50 was  deemed an appropriate pseudovirus input
and used for all subsequent neutralization assays.
Inter-assay reproducibility of neutralizing antibody titers was
demonstrated by including in every experiment a vaccinee serum
pool control, comprising study sera selected following an ini-
tial neutralization screen against HPV16, HPV18, HPV31, HPV45,
HPV52 and HPV58. Median (IQR; n) neutralization titers were
as follows: HPV16 65,564 (59,607–82,880; 30); HPV31 449
(322–499; 26); HPV33 62 (57–75; 25); HPV35 21 (17–24; 26);
HPV52 43 (33–59; 25); HPV58 413 (370–507; 25); HPV18 17,632
(14,660–21,593; 14); HPV39 <20 (N/A; 6); HPV45 70 (43–89; 9);
HPV59 <20 (N/A; 7); HPV68 <20 (N/A; 7); BPV <20 (N/A; 19). As
HPV39, 59, 68 and BPV were not neutralized by this control serum
pool, neutralization tests using these pseudoviruses were repeated
against all study sera to conﬁrm the lack of activity and included
Heparin (H-4784; Sigma, UK) as a positive inhibitor control. All
A7, A9 and BPV pseudoviruses were sensitive to heparin with a
median 80% inhibition concentration of 14.3 (IQR, 3.2–21.9) g/mL
[27–29].
A small panel of nine sera samples was also retested at the end
of the study against six pseudoviruses HPV16, 31, 33, 35, 52 and 58
(n = 54; linear regression, r2 = 0.983; Wilcoxon Paired Signed Rank
Test for differences between groups, p = 0.629).
2.3. Data analysis
2-tailed Fisher’s exact test and two sample Wilcoxon rank-sum
(Mann–Whitney) test were used to compare proportions of indi-
viduals with positive neutralizing antibody and antibody titers of
vaccinees versus HPV-naïve individuals, respectively. Spearman’s
and Kendall’s rank correlations and Pearson’s product-moment
correlation were used to compare the neutralizing antibody titers
against non-vaccine types and the corresponding vaccine type
within a species group. Wilcoxon paired signed rank test was  used
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Table 1
Cross-neutralization of A9 and A7 pseudoviruses by bivalent vaccine or HPV-naïve sera.
Clade PsV Vaccinees HPV-naïve p valueb
Median (IQR) titera Median (IQR) titer
N (%) All Positives N (%) All Positives
A9 16 69 (100) 19,258 (11,730–28,132) 19,258 (11,730–28,132) 0 (0.0) 10 (10–10) N/A <0.001
31  60 (87.0) 78 (40–173) 96 (50–203) 1 (1.0) 10 (10–10) 23 (23–23) <0.001
33 29 (42.0)  10 (10–27) 29 (25–54) 0 (0.0) 10 (10–10) N/A <0.001
35 15  (21.7) 10 (10–10) 30 (25–67) 1 (1.0) 10 (10–10) 23 (23–23) <0.001
52  22 (31.9) 10 (10–21) 25 (21–30) 4 (3.8) 10 (10–10) 27 (26–27) <0.001
58  10 (14.5) 10 (10–10) 33 (25–45) 0 (0.0) 10 (10–10) N/A <0.001
A7 18 69 (100) 4775 (2442–14,149) 4775 (2442–14,149) 1 (1.4) 10 (10–10) 25 (25–25) <0.001
39 0 (0.0)  10 (10–10) N/A 0 (0.0) 10 (10–10) N/A N/A
45 29 (42.0) 10 (10–45) 48 (31–85) 0 (0.0) 10 (10–10) N/A <0.001
59 1  (1.4) 10 (10–10) 30 (30–30) 1 (1.4) 10 (10–10) 23 (23–23) 0.976
68  1 (1.4) 10 (10–10) 98 (98–98) 0 (0.0) 10 (10–10) N/A 0.310
BPV  0 (0.0) 10 (10–10) N/A 0 (0.0) 10 (10–10) N/A N/A
N/A, not applicable.
a Number of samples with neutralizing antibody titers ≥ 20 and, in parentheses, percentage of total vaccinee sera (n = 69) and HPV-naïve sera (A9, n = 104; A7, n = 71; and
BPV, n = 98) tested. Median (IQR, interquartile range) neutralizing antibody titers of all responses, by assigning an arbitrary value of 10 to titers < 20, or only those considered
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aositive (neutralizing antibody titers ≥ 20).
b Two-sample Wilcoxon rank-sum (Mann–Whitney) test for comparison between
btained when examining the proportion of sera positive for neutralizing antibody
sing 2-tailed Fishers Exact test.o determine whether the range of neutralizing antibody titers
gainst two HPV types were different. Kruskal–Wallis equality-
f-populations rank test and the test for trend across ordered
roups (trend analysis) were used to assess the difference between
able 2
omparison of cross-neutralizing antibody titers with type-speciﬁc titers.
Clade HPV Tertilea Titerb
Median (IQR) p value
A9 31 Low 34 (10–71) 
Middle 78 (47–169)
High 195 (92–490) <0.001 
33 Low  10 (10–10) 
Middle 10  (10–31) 
High 23 (10–46) 0.003 
35 Low  10 (10–10) 
Middle 10 (10–10) 
High 10 (10–29) 0.003
52 Low  10 (10–10) 
Middle 10 (10–26) 
High 10 (10–24) 0.009 
58 Low  10 (10–10) 
Middle 10 (10–10) 
High 10 (10–21) 0.013 
A7 39 Low  10 (10–10) 
Middle 10 (10–10) 
High 10 (10–10) N/A 
45 Low  10 (10–16) 
Middle 10 (10–36) 
High 31 (10–76) 0.003 
59 Low  10 (10–10) 
Middle 10 (10–10) 
High 10 (10–10) 0.221 
68 Low  10 (10–10) 
Middle 10 (10–10) 
High 10 (10–10) 0.221 
/A, not applicable.
a Tertiles based on equal distribution (n = 23 sera per tertile) of type-speciﬁc neutral
15,788–20,949]; High: 48,687 [29,016–95,043]) and HPV18 (Low: 1929 [1250–2399]; M
b Median (IQR) neutralization titer for all samples in each tertile (n = 23), substituting 10
ssociations highlighted in bold type.
c Number of sera positive for neutralizing antibody against indicated HPV type and, in 
d Median (IQR) percentage of type-speciﬁc neutralization titer using samples positive fo
ssociations highlighted in bold type.utralization titers using vaccinee and vaccine-naïve sera. Similar associations were
st HPV16, 31, 33, 35, 52, 58, 18 and 45 (p < 0.001), HPV59 (1.000) and 68 (0.493),non-vaccine  type neutralization data ordered into tertiles based
upon neutralizing antibody titers against the vaccine type. All tests
were performed using the statistical package, Stata 10.1 (StataCorp,
College Station, TX).
N (%)c % of type-speciﬁc titerd
 Median (IQR) p value
16 (70) 0.69 (0.47–1.08)
21 (91)  0.49 (0.25–1.07)
23 (100) 0.29 (0.17–0.77) 0.018
4 (17) 0.26 (0.23–0.29)
11 (48) 0.18 (0.12–0.25)
14 (61) 0.07 (0.04–0.12) 0.002
1 (4) 0.22 (0.22–0.22)
5 (22) 0.12 (0.11–0.24)
9 (39)  0.10 (0.03–0.11) 0.023
2 (9) 0.30 (0.24–0.35)
10 (43) 0.13 (0.12–0.16)
10 (43) 0.04 (0.03–0.05) <0.001
1 (4) 0.27 (0.27–0.27)
2 (9) 0.16 (0.14–0.18)
7 (30) 0.03 (0.02–1.17) 0.269
0 (0) N/A
0 (0) N/A
0 (0) N/A N/A
6 (26) 2.02 (1.14–3.47)
8 (35) 1.00 (0.75–1.55)
15 (65) 0.18 (0.13–0.35) <0.001
0 (0) N/A
0 (0) N/A
1 (4) N/A N/A
0 (0) N/A
0 (0) N/A
1 (4) N/A N/A
ization titers for HPV16 (Low: median 7763 [IQR, 5305–11,438]; Middle: 19,258
iddle 4775 [4104–7209]; High: 20,582 [15,177–68,027]).
 for a neutralization titer of <20. p value generated by trend analysis with signiﬁcant
parentheses, percentage of total (n = 23) sera in each tertile.
r cross-neutralizing antibodies. p value generated by trend analysis with signiﬁcant
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Fig. 1. Cross-neutralization neutralizing antibody titers are related to vaccine-type
neutralizing  antibody titers for A9 HPV types (top panel) and A7 HPV types (bottom
panel).  Neutralizing antibody data for non-vaccine types segregated according to
Low (L), Middle (M)  and High (H) vaccine-type tertiles. Plot shows box (median,
IQR),  whisker (±1.5 IQR) and outliers (>1.5 IQR). p values represent association by588 E. Draper et al. / Vac
. Results
Sixty-nine serum samples were collected a median 5.9 (IQR
.7–6.0) months after receiving a third dose of the Cervarix® vac-
ine.
As expected, all (n = 69, 100%) individuals generated high
iter neutralizing antibodies against HPV16 and HPV18 following
accination (Table 1), with HPV16 titers a median 3.5 (IQR, 1.7–5.8)
old higher than the corresponding HPV18 titers (Wilcoxon paired
igned rank test; p < 0.001). Sera capable of neutralizing non-
accine A9 HPV types were commonly found among this group
f vaccinees (ranging from 15% to 87% of individuals, depending
n the HPV type) with neutralization detected most frequently for
PV31, followed by (in order) 33, 52, 35, and 58. Sera capable of
eutralizing non-vaccine HPV types within the A7 species group
ere fewer and almost completely restricted to reactivity against
PV45. No inhibition of the control BPV pseudovirus was  seen
sing these vaccine sera.
.1.  Speciﬁcity of the pseudovirus neutralization assay for
accine-induced responses
Little  or no non-speciﬁc inhibition of pseudovirus entry was
een using the HPV-naïve sera resulting in an apparent assay speci-
city of 99–100% (Table 1). The exception was pseudovirus HPV52
hich was inhibited by four sera, albeit to low titer, resulting in
n apparent speciﬁcity of 95% (95% CI, 90–100) for this HPV type.
o inhibition of the control BPV pseudovirus was seen using these
PV-naïve sera.
.2.  Association of vaccine-type and non-vaccine type responses
Signiﬁcant associations were found between the neutraliz-
ng antibody titers observed against HPV31, 33, 35, 45, 52 and
8 and the titers observed against their related vaccine-type
Spearman’s and Kendall’s rank correlation, p < 0.005; data not
hown). However, using the more stringent Pearson’s product-
oment correlation coefﬁcient only HPV31 (r = 0.855; p < 0.001),
PV33 (r = 0.523; p < 0.001), HPV35 (r = 0.269; p = 0.026) and HPV45
r = 0.485; p < 0.001) gave signiﬁcant associations with their respec-
ive type-speciﬁc titers. As expected [12], a signiﬁcant correlation
as found between the neutralizing antibody titers for HPV16
nd HPV18 (Spearman’s rho = 0.673; p < 0.001; Pearson’s r = 0.657;
 < 0.001).
The relationship between vaccine-type and non-vaccine type
eutralization was further investigated by subdivision of the sera
nto tertiles based on the vaccine-type titers for each species group
HPV16 tertiles for A9 types and HPV18 tertiles for A7 types). For
PV types 31, 33, 35, 45 and 58 the percentage of individuals with a
ositive, non-vaccine type neutralization titer increased with each
ertile of vaccine-type titer (Table 2). For example, 70% of individ-
als in the low HPV16 tertile had a positive neutralizing antibody
iter against HPV31, rising to 91% for the middle and 100% for indi-
iduals in the high HPV16 tertile. This was not the case for HPV52,
owever, which demonstrated no increase in positivity between
he middle and high tertiles. The number of non-vaccine types neu-
ralized per serum increased with type-speciﬁc tertile such that
he median number of non-vaccine types neutralized by sera in
he lowest HPV16 tertile was 1.0 (IQR, 0.5–1.5) compared with 2.0
2.0–2.5) and 3.0 (IQR, 1.5–4.0) for the middle and high tertiles,
espectively.
Neutralizing antibody titers against non-vaccine types HPV31,
3, 35, 45, 52 and 58 increased in association with increasing
accine-type tertiles (Table 2 and Fig. 1). For example, for HPV31,
he median (IQR) titer was 34 (10–71) for the low HPV16 tertile,
ising to 78 (47–169) for the middle and 195 (92–490) for the hightrend across tertiles: *p < 0.05; **p < 0.01; ***p < 0.001; NSp > 0.05.
HPV16 tertile. Signiﬁcant associations were found between cross-
neutralizing titers for non-vaccine types and vaccine-type tertile for
HPV31, 33, 35, 45, 52 and 58) when assessed by the Kruskal–Wallis
test (data not shown) or the test for trend across ordered groups
(Table 2 and Fig. 1). As expected, HPV18 neutralizing antibody titers
were signiﬁcantly associated with increasing HPV16 tertiles (trend
analysis and Kruskal–Wallis test; p < 0.001).
3.3.  Relative magnitude of cross-neutralizing antibody responses
Cross-neutralization titers were overall very low, being <1%
of the respective type-speciﬁc, HPV16 or HPV18 titer: for exam-
ple, HPV31 (median 0.49% [IQR 0.24–1.02%]), HPV33 (0.13%
[0.09–0.24%]) and HPV45 (0.50% [0.18–1.02%]). In contrast to the
increase across the vaccine-type tertiles of the percentage of indi-
viduals with, and levels of, cross-neutralizing titers (Table 2),
the relative magnitude of non-vaccine to vaccine titers decreased
across the tertiles. For example for HPV31, the median (IQR) per-
centage of type-speciﬁc titer was  0.69% (0.47–1.08%) for the low
HPV16 tertile, falling to 0.49% (0.25–1.07%) for the middle and 0.29%
(0.17–0.77%) for the high HPV16 tertile (trend analysis; p = 0.018).
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. Discussion
In this study we have attempted to estimate the propensity for
erum taken from 13 to 14 year old girls recently vaccinated with
he bivalent HPV vaccine to neutralize pseudoviruses represent-
ng genetically related, non-vaccine HPV types within the A9 and
7 species groups. Neutralizing antibodies against non-vaccine A9
PV types were commonly detected within this study group, with
ntibodies against HPV31 and HPV33 being the most frequently
etected and of the highest titer. The only A7 non-vaccine HPV type
or which a signiﬁcant neutralizing antibody response was found
as HPV45.
Neutralizing antibody titers against HPV31, 33, 35, 45 (and to
 lesser extent HPV52 and 58) were signiﬁcantly associated with
heir related vaccine-type antibody titers, suggesting that the gen-
ration of cross-neutralizing antibodies is at least coincident with
he host immune response to vaccination. No signiﬁcant neutraliza-
ion was seen against the A7 HPV types 39, 59 and 68 or the control
PV. It is noteworthy perhaps that the individuals with a positive
eutralizing antibody score against either HPV59 or HPV68 were
lso in the highest tertile of vaccine-type HPV18 neutralizing anti-
ody titers, suggesting that responses against these types, although
ot signiﬁcant overall and a rare occurrence (<5% of vaccinees), may
ndeed be vaccine-related. The fewer number of samples positive
or neutralizing antibodies against non-vaccine HPV types from the
7 species group, being almost exclusively directed against HPV45,
han from the A9 species group, is likely to be related to the lower
3.5 fold) titers generated against the vaccine-type HPV18 com-
ared to HPV16, which appears to be a common ﬁnding for the HPV
accines [12,30–32]. Cross-neutralizing antibody titers were sub-
tantially lower (<1%) than vaccine-type titers and the gap between
hese two measures widened with increasing vaccine-type titer.
hese observations suggest that individuals who  elicit the high-
st antibody responses against vaccine types generate the highest
bsolute levels of cross-reactive antibodies but the lowest cross-
eactive responses as a function of their vaccine-type responses,
erhaps reﬂecting the immunodominance of the type-speciﬁc neu-
ralizing epitope(s) relative to the cross-reactive epitope(s).
A  recent study [20] provided evidence for signiﬁcant cross-
eutralization of HPV31 and HPV45 (but not HPV52 and HPV58)
seudovirions using sera taken from 18 to 25 year old women six
onths after immunization with the bivalent HPV vaccine as part of
 clinical trial in Costa Rica [33]. Antibody cross-reactivity against
PV45 has also been reported for the quadrivalent HPV vaccine,
ardasil® [21]. The discrepant observations concerning HPV52 and
PV58 between this study and the analysis by Kemp et al. [20] may
e due to differences in the ages of the study participants, a param-
ter known to have an impact on HPV vaccine immunogenicity
31].
We have expanded the currently available panel of HPV L1L2
seudoviruses to represent all those HPV types within the vaccine-
elated A9 (16, 31, 33, 35, 52, and 58) and A7 (18, 39, 45, 59,
8) species groups that have been considered by the International
gency for Research on Cancer to be at least ‘probably carcinogenic
o humans’ [13]. We  are not aware of any published data on the
easurement of cross-neutralizing antibodies elicited against the
losely related, non-vaccine types HPV33, HPV35, HPV39, HPV59
nd HPV68 by either HPV vaccine.
We did not have pre-vaccine sera, or sera from unvaccinated
3–14 year old girls, with which to gauge background levels of
aturally induced HPV antibodies and non-speciﬁc assay interfer-
nce. However, the sera included in our study were from young
irls close to the target age (12 years) for routine HPV immuniza-
ion in the UK and within an age-group where the level of naturally
nduced antibodies was expected to be very low [34]. This leads
s to believe that signiﬁcant confounding due to prior infection (2011) 8585– 8590 8589
with,  and immune response to, non-vaccine types to be highly
unlikely. Our assessment of non-speciﬁc interference using sera
from HPV-naïve infants resulted in a pseudovirus neutralization
assay speciﬁcity of around 99–100%.
As the sera used for this study were collected within six
months of the third vaccine dose and given the apparent
improved immunogenicity within this age group [31], the titers of
cross-neutralizing antibodies reported here are likely to represent
peak levels. Type-speciﬁc neutralizing antibodies appear to wane
quite quickly following vaccination to plateau several fold lower
than their peak level [35] and this is likely to be true also for
cross-neutralizing antibodies. We  did not have repeat samples or a
sufﬁcient range in collection times to assess changes in neutralizing
antibody titers over time.
The  detection of cross-neutralizing antibodies in vaccine sera
per se does not, of course, provide sufﬁcient evidence for antibodies
being mechanistically associated with cross-protection. Further-
more, type-speciﬁc antibody titers in genital secretions are orders
of magnitude lower than those found in the periphery [12] and
it is unclear whether these very low levels of cross-neutralizing
antibodies  found in the periphery would be sufﬁcient to protect
at the site of infection in the absence of other immune effectors
[36,37]. However, the coincidence of the rank order of HPV types
recognized by vaccinee sera in this and other studies [20] and the
apparent hierarchy of protected HPV types suggested from efﬁcacy
studies [4,16,17] is intriguing. Deﬁning the mechanism(s) of cross-
protection will be important to monitor vaccine effectiveness on
both a population and individual level.
These data may  be helpful to parameterize epidemiological
models to predict the impact of the current HPV vaccines on the
population and to inform the development of second generation
HPV vaccines.
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